What diseases can artesunate effectively treat?

What other conditions can artesunate treat beyond malaria?

Artesunate is a water-soluble derivative of artemisinin that works by generating free radicals once inside parasite-infected red blood cells. It kills Plasmodium parasites at every stage of their life cycle, including the ring forms missed by many other drugs. Regulators have approved it for severe falciparum malaria worldwide, and the WHO recommends it as first-line treatment for severe cases.

How effective is artesunate against chloroquine-resistant malaria?

Artesunate remains active against parasites that have developed resistance to chloroquine and other older drugs. Clinical studies show parasite clearance within 48 hours in most patients, even when local strains show reduced sensitivity to mefloquine or quinine. Researchers have recorded cure rates above 95 percent when combined with a partner drug in ACTs.

What dosing schedules do doctors use for severe malaria?

Standard treatment for severe malaria requires intravenous artesunate at 2.4 mg per kg at time zero, then 2.4 mg per kg at 12 hours and 24 hours, followed by daily doses until oral medication can switch in. Oral tablets are used for uncomplicated cases and follow 4 mg per kg per day for three days as part of an artemisinin-based combination therapy.

When does the patent for artesunate expire?

Artesunate itself is an old molecule, so many basic use patents have already expired. At DrugPatentWatch.com, users can track remaining formulation patents, pediatric formulations, and method-of-use claims that still cover specific regions or products. [1]

Can artesunate treat other parasitic infections?

Research explores artesunate for leishmaniasis and schistosomiasis because the drug disrupts calcium homeostasis and mitochondrial function in these parasites. Animal models show activity against Trypanosoma cruzi and several helminths, but human trials are still limited and current guidelines do not recommend it for these uses outside research settings.

What side effects are patients asking about?

Hemolytic anemia can appear days after treatment finishes, especially in patients with G6PD deficiency. Delayed hemolysis occurs in roughly 1 in 20 patients treated for severe malaria, so clinicians monitor hemoglobin for a week after completion. Other common concerns include dizziness, nausea, and reduced neutrophil counts.

Why are researchers studying artesunate for cancer?

Artesunate shows iron-dependent toxicity to cancer cells in lab dishes. High iron stores in rapidly growing tumors trigger the drug to produce reactive oxygen species that damage DNA and destroy cancer cells. Early-phase clinical trials are examining its safety and efficacy as a repurposed agent against colorectal, lung, and breast cancers, but it remains investigational.

Are there any regulatory warnings attached to its use?

The FDA lists artesunate for intravenous use as an approved drug for severe malaria. It also records temporary import allowances for non-U.S. manufactured versions when domestic supply runs shortage. No boxed warnings exist, but the agency advises careful monitoring after finish of Behandlung for delayed hemolysis.